Posts

Showing posts with the label investment opportunities

ATC Energies IPO to make its debut today. Check GMP ahead of listing

Image
[hfe_template id='11223'] [ad_1] Contrary to another IPO of Shri Ahimsa, which opened on the same day, ATC Energies System's offering received a muted subscription from investors. However, the company's shares will debut on the NSE SME platform today. The GMP ahead of the listing is around 3%. Net proceeds to the tune of Rs 64 crore will be used for repayment of debt, funding capex requirements, working capital and general corporate purposes. The issue, which included a fresh equity sale and an offer for sale, was subscribed just over 1x. On the other hand, the public offer of Shri Ahimsa was booked over 60 times. ATC Energies produces and supplies lithium-ion batteries, offering efficient and cost-effective energy storage solutions for industries such as banking and automobiles. It operates factories in Vasai, Thane, and Noida, equipped with advanced machinery, an integrated development and assembly system, and quality testing facilities across a total area of a...

Opportunities & risks: Rohit Seksaria shares what investors need to know

Image
[hfe_template id='11223'] [ad_1] Rohit Seksaria of Sundaram Mutual, known to find gems within the small and mid end of the market, shared his insights on the broader market trends in a recent interaction with ETNow, while discussing how the recent corrections have impacted these stocks and provided his perspective on where investors should focus their attention. Additionally, he elaborated on his views regarding the lending financials, consumer discretionary sectors, and the global cyclical industries, highlighting the opportunities and risks present in the current market scenario: Outlook for small and mid cap stocks Rohit Seksaria believes that opportunities will always exist in the market, particularly in the small-cap space, where investors can find promising stocks despite fluctuations. He acknowledged that while the broader market has witnessed a significant correction in the mid and small-cap segments, they still remain slightly more expensive compared to large-ca...

Waaree Energies shares surge 14% as Q3 profit soars 296% YoY to Rs 493 crore

Image
[hfe_template id='11223'] [ad_1] Shares of Waaree Energies climbed as much as 14.4% on Friday to Rs 2,505.85 on the BSE, after the renewable energy firm reported a 296% year-on-year (YoY) jump in consolidated net profit for Q3FY25. The company posted a net profit of Rs 493 crore for the quarter ended December 2024, compared to Rs 124 crore in the same period last year. Revenue from operations stood at Rs 3,457 crore, marking a 117% increase from Rs 1,596 crore in Q3FY24. However, on a sequential basis, revenue declined by 3.2% from Rs 3,574 crore in the previous quarter (Q2FY25), while profit after tax (PAT) rose 36% from Rs 362 crore. Despite a significant rise in profitability, total expenses increased to Rs 2,855 crore in Q3FY25, compared to Rs 1,517 crore a year earlier. However, expenses declined quarter-on-quarter from Rs 3,165 crore in Q2FY25. The company also reported a 257% YoY surge in EBITDA, with margins expanding to 22.84% from 13.73% in Q3FY24. Meanwhile, i...

Largecap stocks: How to solve for the ‘missing’ middle order?

Image
[hfe_template id='11223'] [ad_1] I recently asked ChatGPT to name some of the most underrated cricketers of all-time. ETMarkets.com Source: ChatGPT Interestingly, the response it gave had one common thread: all of them were middle-order players. While GPT’s responses may vary based on timing and prompts, one thing seems to be pretty clear: in a world obsessed with flashy openers, flamboyant power hitters and lightning-fast bowlers, the middle-order players often end up not getting the recognition they deserve. Yet, it’s these players who play a pivotal role in helping teams win tournaments. They bring balance to the team with their dependable run-scoring, stellar fielding, and sharp bowling skills. But what does this have to do with investing? Given the equity market volatility in recent months, there seems to be a renewed interest in large cap stocks.At first glance, it looks like large cap investors have a wide variety of options – perhaps too many - with indices such ...

IPO Calendar: 4 new issues, 7 listings to keep primary markets busy next week

Image
[hfe_template id='11223'] [ad_1] The primary market will see four new IPOs opening for subscription next week including three in the SME segment. Apart from these new issues, the Street will also witness 7 listings. Going forward, the primary market momentum for the rest of the year looks strong with some bankers expecting as many as 1,000 IPOs in the next two years. Here's what to look forward to on IPO front next week Denta Water and Infra IPO Denta Water and Infra Solutions IPO will open on January 22 for subscription and will close on January 24. Investors can bid for a minimum of 50 equity shares in one lot for which the price band has been set at Rs 279 to Rs 294 apiece. The IPO is entirely a fresh issue of equity shares up to 75,00,000 with no offer for sale component. The proceeds from its fresh issuance to the extent of Rs 150 crore will be utilized for meeting working capital requirements; and general corporate purpose, subject to the applicable laws. Estab...

Stocks to buy today: SAIL, Aurobindo Pharma and Piramal Enterprises on investors' radar

Image
[hfe_template id='11223'] [ad_1] Equity indices Sensex and Nifty rebounded sharply on Monday after five days of steep decline amid value buying at lower levels and a supportive trend in global markets. Stocks that were in focus include names like SAIL, which rose 4% and Aurobindo Pharma, which gained 1% and HPCL, whose shares declined nearly 1% on Monday. Here's what Ameya Ranadive, CMT, CFTe, Sr Technical Analyst at StoxBox, recommends investors should do with these stocks when the market resumes trading today. SAIL Steel Authority of India Ltd (SAIL), currently trading at Rs 121, offers an attractive risk-reward setup after a significant correction from its recent highs. The stock is consolidating near crucial support levels, with the downside risk mitigated as long as it holds above Rs 110. Technical indicators like RSI, currently at 51, show a bullish divergence, suggesting the potential for a rebound. Additionally, the ADX indicates weakening selling momentum, w...

FPIs log Rs 21,789 crore inflows in December so far, reversing months of outflows

Image
[hfe_template id='11223'] [ad_1] Foreign portfolio investors (FPIs) recorded net equity inflows of Rs 21,789 crore in December so far, marking a significant reversal after months of heavy outflows. With this surge in December, FPIs have experienced a total net inflow of Rs 6,770 crore in 2024, compared to outflows of Rs 15,019 crore at the end of November. This turnaround comes after heavy off-loading in domestic equities in the last two months, with net outflows of Rs 21,612 crore in November and Rs 94,017 crore in October. In the first half of December, nearly 83% of FPI flows were concentrated in three sectors — financial services, IT, and real estate. These sectors attracted inflows of Rs 7,424 crore, Rs 6,754 crore, and Rs 4,689 crore, respectively. At the same time, FPIs sold Rs 5,337 crore worth of oil and gas stocks, Rs 1,823 crore of auto stocks, and Rs 1,655 crore of FMCG shares. Despite these shifts, telecom and services, which had seen outflows in November, s...

Top picks post Q2 results: ICICI Bank, ONGC could give 30-60% return in 1 year

Image
[hfe_template id='11223'] [ad_1] The 2QFY25 corporate earnings report revealed a weaker-than-expected overall performance, with Nifty earnings growing by just 4% YoY, in line with estimates. This marks the second consecutive quarter of single-digit growth for the Nifty, a trend not seen since the pandemic's onset in June 2020. The aggregate performance was hit by a drag from global commodities (i.e. Metals and O&G). Excluding the same, Nifty posted 11% earnings growth. Looking at sectoral performance, the BFSI sector was a standout performer, driven by robust growth in public sector banks, which reported a 34% YoY increase in earnings, well ahead of expectations. Non-lending NBFCs also performed exceptionally, posting a 92% YoY growth. Technology (+8% YoY ) companies continued to deliver healthy performance, although the outlook remains slightly guarded as client spending remains uncertain, particularly in discretionary areas. The healthcare sector showed resilie...

Hot Stocks: Brokerages see 11-30% upside in Apollo Tyres, Eicher Motors & L&T

Image
[hfe_template id='11223'] [ad_1] Global brokerage firms have shared their insights on key stocks, highlighting investment opportunities with potential upsides. Goldman Sachs has reiterated its confidence in Eicher Motors and Larsen & Toubro (L&T), citing strong growth drivers and robust performance indicators. Meanwhile, UBS has maintained its bullish stance on Apollo Tyres, emphasizing a promising outlook despite mixed quarterly results. Here's a closer look at their assessments and growth prospects for these stocks. We have collated a list of recommendations from top brokerage firms from ETNow and other sources: Goldman Sachs on Eicher Motors: Buy| Target Rs 5400: LTP Rs 4589| Upside 17% Goldman Sachs has maintained its Buy rating on Eicher Motors with a target price of Rs 5,400, implying a potential upside of 17% from its last traded price of Rs 4,589. The company’s Q2 performance was in line with expectations, supported by a favorable product cycle and ro...

Patent cliff can turn Indian pharma stocks into investor’s goldmine

Image
[hfe_template id='11223'] [ad_1] Over the past few months, the market witnessed a sharp rally in pharma sector stocks, one of the key drivers behind this surge is ‘Patent Cliff.’ A Patent cliff occurs when a significant number of drug patents expire and other companies are allowed to manufacture similar drug. Typically, the patent of a drug lasts for 20 years, during which the innovator company enjoys a monopoly in the market and hence commands the premium on that drug's pricing. This period of exclusivity allows companies to maximize their revenues, profits, and overall growth. Upon patent expiry, the other generic drug manufacturers step into the game and they are allowed to produce and sell the same drug under a different brand name. Due to the sudden influx of manufacturers, the volumes of the drug skyrocket for production ultimately leading to lower cost of manufacturing and lower pricing of the end medicine. The Impact on Pharmaceutical Industry This industry r...